NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

CRNX

Crinetics Pharmaceuticals Inc

Jul 09 • 04:00PM ET

32.33

Dollar change +2.96
Percentage change 10.08	%

Healthcare • Biotechnology • USA • NASD

Peers: NBIX LLY PFE NVS BMRN VRTX REGN SNY MRK BMY

| Held by: VTI VB IWM VXF VBK XBI IWO IBB VTWO SCHA

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-3.82	Insider Own	7.49%	Shs Outstand	93.53M	Perf Week	13.72%
Market Cap	3.03B	Forward P/E	-	EPS next Y	-4.63	Insider Trans	-1.89%	Shs Float	86.67M	Perf Month	-2.06%
Enterprise Value	1.80B	PEG	-	EPS next Q	-1.10	Inst Own	104.80%	Short Float	11.91%	Perf Quarter	22.55%
Income	-328.25M	P/S	8413.01	EPS this Y	-21.70%	Inst Trans	2.18%	Short Ratio	12.77	Perf Half Y	-39.17%
Sales	0.36M	P/B	2.41	EPS next Y	-3.07%	ROA	-28.06%	Short Interest	10.32M	Perf YTD	-36.77%
Book/sh	13.41	P/C	2.38	EPS next 5Y	4.65%	ROE	-30.84%	52W High	62.53 -48.30%	Perf Year	-26.24%
Cash/sh	13.61	P/FCF	-	EPS past 3/5Y	-9.67% -12.11%	ROIC	-25.29%	52W Low	24.10 34.15%	Perf 3Y	71.51%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-1.22% -	Gross Margin	-796.40%	Volatility	4.86% 3.96%	Perf 5Y	83.07%
Dividend TTM	-	EV/Sales	5013.57	EPS Y/Y TTM	-1.20%	Oper. Margin	-104467.87%	ATR (14)	1.32	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	22.53	Sales Y/Y TTM	-100.00%	Profit Margin	-90928.53%	RSI (14)	59.49	Recom	1.07
Dividend Gr. 3/5Y	- -	Current Ratio	22.53	EPS Q/Q	-12.26%	SMA20	5.92%	Beta	0.33	Target Price	74.07
Payout	-	Debt/Eq	0.04	Sales Q/Q	-	SMA50	3.57%	Rel Volume	1.49	Prev Close	29.37
Employees	437	LT Debt/Eq	0.04	Earnings	May 08 AMC	SMA200	-22.33%	Avg Volume	808.00K	Price	32.33
IPO	Jul 18, 2018	Option/Short	Yes / Yes	EPS/Sales Surpr.	-10.54% 162.55%	Trades		Volume	1,201,902	Change	10.08%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-25-25	Initiated	Stifel	Buy	$60
Feb-11-25	Initiated	TD Cowen	Buy
Feb-04-25	Initiated	Wolfe Research	Peer Perform
Jan-22-25	Upgrade	Jefferies	Hold → Buy	$55
Mar-06-24	Initiated	Citigroup	Buy	$68
Jan-16-24	Initiated	Morgan Stanley	Overweight	$50
Dec-21-23	Initiated	Jefferies	Hold	$35
Nov-20-23	Resumed	JP Morgan	Overweight	$35
Oct-24-23	Resumed	Cantor Fitzgerald	Overweight	$52 → $50
Aug-31-23	Initiated	Oppenheimer	Outperform	$40
Apr-24-23	Initiated	Piper Sandler	Overweight	$56
Mar-30-23	Initiated	Robert W. Baird	Outperform	$48
Nov-30-21	Initiated	JMP Securities	Mkt Outperform	$43
Nov-23-21	Initiated	Evercore ISI	Outperform	$68
Jun-18-21	Upgrade	JP Morgan	Neutral → Overweight	$28
Dec-23-19	Initiated	ROTH Capital	Buy	$37
Feb-14-19	Initiated	H.C. Wainwright	Buy	$35
Aug-13-18	Initiated	Piper Jaffray	Overweight	$40
Aug-13-18	Initiated	Leerink Partners	Outperform	$43
Aug-13-18	Initiated	JP Morgan	Neutral	$29

Show Previous Ratings

Jul-08-25 08:21AM	Should You Hold Crinetics Pharmaceuticals (CRNX)? (Insider Monkey)
Jul-03-25 08:17AM	Ionis Pharmaceuticals (IONS) Moves 9.1% Higher: Will This Strength Last? (Zacks)
Jun-30-25 04:05PM	Crinetics to Showcase the Next Generation of Endocrinology Innovation at ENDO 2025 with Eight Presentations From its Deep Pipeline (GlobeNewswire)
Jun-16-25 08:00AM	Crinetics Pharmaceuticals to Host R&D Day on June 26, 2025 (GlobeNewswire)
Jun-10-25 04:29PM	Crinetics Pharmaceuticals Announces June 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
08:00AM	Loading…
May-23-25 08:00AM	Crinetics Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2025 (GlobeNewswire)
May-15-25 04:05PM	Crinetics to Present New Research on Paltusotine, Atumelnant and Unmet Needs in Acromegaly Treatment at the American Association of Clinical Endocrinology Annual Meeting 2025 (GlobeNewswire)
May-12-25 04:05PM	Crinetics Pharmaceuticals Announces May 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +8.60% -7.11%
May-09-25 01:01PM	Crinetics Pharmaceuticals Inc (CRNX) Q1 2025 Earnings Call Highlights: Strategic Growth and ... (GuruFocus.com) -6.18%
08:48AM	Is Crinetics Pharmaceuticals, Inc. (CRNX) The Best Stock That Will Bounce Back? (Insider Monkey)
May-08-25 05:40PM	Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Crinetics Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
May-07-25 09:57AM	What To Expect From Crinetics Pharmaceuticals Inc (CRNX) Q1 2025 Earnings (GuruFocus.com)
Apr-11-25 08:00AM	Crinetics Pharmaceuticals to Report First Quarter 2025 Financial Results on May 8, 2025 (GlobeNewswire) +8.42%
Apr-10-25 05:04PM	Crinetics Pharmaceuticals Announces April 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
02:15PM	Loading…
Apr-02-25 02:15PM	Crinetics Pharma: Strong Progress With Multiple Indications And Upcoming PDUFA (Seeking Alpha)
Mar-27-25 04:05PM	Crinetics Pharmaceuticals Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) and Orphan Drug Designation (ODD) for Paltusotine in Acromegaly (GlobeNewswire)
Mar-10-25 04:36PM	Crinetics Pharmaceuticals Announces March 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-27-25 04:05PM	Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire) +7.74%
03:24PM	Is Crinetics Pharmaceuticals (CRNX) the Worst Performing Mid Cap Stock to Buy According to Analysts? (Insider Monkey)
Feb-26-25 07:26AM	What To Expect From Crinetics Pharmaceuticals Inc (CRNX) Q4 2024 Earnings (GuruFocus.com)
Feb-24-25 08:30AM	Crinetics Pharmaceuticals Appoints Tobin Schilke as Chief Financial Officer (GlobeNewswire) -7.58%
Feb-20-25 04:05PM	Crinetics Pharmaceuticals to Participate in Two Upcoming March Investor Conferences (GlobeNewswire)
Feb-10-25 04:44PM	Crinetics Pharmaceuticals Announces February 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-06-25 04:35PM	Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025 (GlobeNewswire)
Feb-05-25 04:57PM	Crinetics Pharmaceuticals, Inc. (CRNX): One of Januarys Biggest Losers (Insider Monkey)
Jan-29-25 05:37PM	What Are Analysts Talking About Crinetics Pharmaceuticals (CRNX)? (Insider Monkey)
Jan-21-25 04:10PM	Is Crinetics Pharmaceuticals (CRNX) Among Billionaire Joseph Edelmans Long-Term Stock Picks? (Insider Monkey)
Jan-17-25 11:12AM	Crinetics Pharmaceuticals, Inc. (CRNX): The Biotech Stock with Biggest Upside Potential (Insider Monkey)
Jan-10-25 05:15PM	Crinetics Pharmaceuticals Announces January 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -16.31%
07:00AM	Loading…
07:00AM	Crinetics Announces Positive Topline Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) (GlobeNewswire)
Jan-06-25 08:00AM	Crinetics Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -5.00%
Dec-16-24 08:00AM	Crinetics Pharmaceuticals Appoints Isabel Kalofonos as Chief Commercial Officer (GlobeNewswire)
Dec-10-24 08:44PM	Crinetics Pharmaceuticals Announces December 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.21%
06:22AM	FDA accepts Crinetics Pharmaceuticals' NDA for acromegaly treatment therapy (Pharmaceutical Business Review)
Dec-09-24 08:00AM	Crinetics Announces FDA Acceptance of New Drug Application for Paltusotine for Adult Patients with Acromegaly (GlobeNewswire)
Nov-15-24 09:00AM	Crinetics Pharmaceuticals to Participate in Three Upcoming December Investor Conferences (GlobeNewswire) -8.28%
Nov-14-24 04:05PM	UPDATE: Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual Meeting (GlobeNewswire)
Nov-13-24 02:18AM	Crinetics Pharmaceuticals Inc (CRNX) Q3 2024 Earnings Call Highlights: Strategic Advances and ... (GuruFocus.com)
Nov-12-24 04:07PM	Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual Meeting (GlobeNewswire)
04:05PM	Crinetics Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Nov-11-24 04:05PM	Crinetics Pharmaceuticals Announces November 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-17-24 03:09PM	State Street Corp's Strategic Acquisition in Crinetics Pharmaceuticals (GuruFocus.com)
Oct-16-24 08:00AM	Crinetics Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 12, 2024 (GlobeNewswire)
Oct-10-24 04:40PM	Crinetics Pharmaceuticals Announces October 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
08:57AM	Morning Movers: Arcadium Lithium surges after deal to be acquired (TipRanks)
Oct-09-24 05:56PM	Crinetics Pharmaceuticals Inc (CRNX) Q2 2024 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com)
Oct-08-24 11:55PM	Crinetics Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock (GlobeNewswire)
04:01PM	Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Sep-26-24 04:05PM	Crinetics Submits New Drug Application for Paltusotine for the Treatment of Acromegaly (GlobeNewswire)
Sep-12-24 07:00PM	Insider Sale: Chief Scientific Officer Stephen Betz Sells Shares of Crinetics Pharmaceuticals ... (GuruFocus.com) +5.02%
Sep-10-24 04:40PM	Crinetics Pharmaceuticals Announces September 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-05-24 01:07AM	Crinetics Pharmaceuticals, Inc. (CRNX): Among the Best Mid-Cap Healthcare Stocks To Buy Now (Insider Monkey)
Sep-02-24 06:05PM	10 Best Mid-Cap Healthcare Stocks To Buy Now (Insider Monkey)
Aug-29-24 04:05PM	Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Aug-28-24 07:01PM	Insider Sale: Chief Scientific Officer Stephen Betz Sells 3,000 Shares of Crinetics ... (GuruFocus.com)
Aug-14-24 07:02PM	Insider Sale: Chief Scientific Officer Stephen Betz Sells 3,000 Shares of Crinetics ... (GuruFocus.com)
Aug-12-24 04:05PM	Crinetics Pharmaceuticals Announces August 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-08-24 09:57PM	CRNX Stock Earnings: Crinetics Pharmaceuticals Misses EPS, Misses Revenue for Q2 2024 (InvestorPlace) +5.05% -6.11%
06:00PM	Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Crinetics Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
08:30AM	Crinetics Launches ACRO/TRUTH Educational Initiative to Raise Awareness of Acromegaly Treatment Challenges (GlobeNewswire)
Aug-01-24 10:01AM	Crinetics Pharmaceuticals, Inc. (CRNX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Jul-26-24 07:00PM	Insider Sale: Chief Scientific Officer Stephen Betz Sells Shares of Crinetics Pharmaceuticals ... (GuruFocus.com)
Jul-18-24 04:05PM	Crinetics Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 8, 2024 (GlobeNewswire)
Jul-12-24 07:01PM	Insider Sale: Chief Scientific Officer Stephen Betz Sells Shares of Crinetics Pharmaceuticals ... (GuruFocus.com)
Jul-10-24 07:29PM	Crinetics Pharmaceuticals Announces July 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.33%
Jun-26-24 07:00PM	Insider Sale: Chief Scientific Officer Stephen Betz Sells Shares of Crinetics Pharmaceuticals ... (GuruFocus.com) -5.97%
02:11PM	7 Biotech Stocks to Boost Your Portfolio to Peak Health (InvestorPlace)
Jun-18-24 04:30PM	EY Announces Scott Struthers, Ph.D., CEO and Founder of Crinetics Pharmaceuticals, as an Entrepreneur Of The Year 2024 Pacific Southwest Award Winner (GlobeNewswire)
Jun-12-24 02:38AM	Insider Sale at Crinetics Pharmaceuticals Inc (CRNX): Chief Scientific Officer Stephen Betz ... (GuruFocus.com) +6.60%
Jun-10-24 06:35PM	Crinetics Pharmaceuticals Announces June 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-03-24 12:16PM	Crinetics Unveils 'Stunning' Results In Highly Anticipated Study (Investor's Business Daily)
12:00PM	Crinetics Presents New Data at ENDO 2024 that Increases Body of Evidence Positioning Once-Daily, Oral Paltusotine as Potential First-Choice Treatment Option for Acromegaly (GlobeNewswire)
12:00PM	Crinetics Announces Positive Initial Findings at ENDO 2024 for Atumelnant in Two Ongoing, Open-Label Studies for the Treatment of Congenital Adrenal Hyperplasia (CAH) and ACTH-Dependent Cushing's Syndrome (ADCS) (GlobeNewswire)
May-31-24 02:46AM	Insider Sale: Chief Scientific Officer Stephen Betz Sells 3,000 Shares of Crinetics ... (GuruFocus.com)
May-30-24 04:05PM	Crinetics Pharmaceuticals Appoints Robert M. Cuddihy, M.D., as Senior Vice President of Medical Affairs (GlobeNewswire)
May-22-24 08:00AM	Crinetics Pharmaceuticals Announces Early Release of ENDO 2024 Late-Breaking Abstracts (GlobeNewswire)
May-16-24 05:23PM	Stanley Druckenmiller Bet On Biotech, Financial Services in Q1, Trimmed Nvidia Stake (Investopedia)
May-13-24 10:53AM	Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-10-24 05:38PM	Crinetics Pharmaceuticals Announces May 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
05:03PM	Crinetics Pharmaceuticals Insider Sold Shares Worth $5,307,931, According to a Recent SEC Filing (MT Newswires)
12:47PM	Crinetics Pharmaceuticals Inc (CRNX) Reports Q1 2024 Financial Results (GuruFocus.com)
May-09-24 08:55PM	CRNX Stock Earnings: Crinetics Pharmaceuticals Misses EPS, Beats Revenue for Q1 2024 (InvestorPlace)
05:35PM	Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
05:03PM	Crinetics Pharmaceuticals Q1 Net Loss Widens (MT Newswires)
04:05PM	Crinetics Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
May-08-24 04:05PM	Crinetics Pharmaceuticals to Present Advancements from Atumelnant (CRN04894) and Paltusotine Development Programs at ENDO 2024 (GlobeNewswire) +6.78%
May-07-24 08:55AM	Piper Sandler Adjusts Price Target on Crinetics Pharmaceuticals to $97 From $56, Maintains Overweight Rating (MT Newswires)
May-02-24 04:05PM	Crinetics Pharmaceuticals to Report First Quarter 2024 Financial Results on May 9, 2024 (GlobeNewswire)
Apr-11-24 04:05PM	Crinetics Pharmaceuticals Announces April 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -7.16%
Mar-28-24 08:10AM	Insiders Are Dumping These 5 Healthcare Stocks (Insider Monkey) +5.36%
Mar-26-24 07:01PM	Insider Sell: COO Jeff Knight Sells 32,359 Shares of Crinetics Pharmaceuticals Inc (CRNX) (GuruFocus.com)
Mar-22-24 07:02PM	Insider Sell: Chief Medical and Development Officer Dana Pizzuti Sells 15,089 Shares of ... (GuruFocus.com)
07:02PM	Director Matthew Fust Sells 60,000 Shares of Crinetics Pharmaceuticals Inc (CRNX) (GuruFocus.com)
Mar-21-24 02:32AM	Crinetics Pharmaceuticals Inc CFO Marc Wilson Sells 6,942 Shares (GuruFocus.com)
Mar-20-24 11:46AM	Crinetics (CRNX) Up as Second Acromegaly Study Meets Goals (Zacks)
05:14AM	Crinetics Pharmaceuticals (CRNX) Stock Jumps 19.1%: Will It Continue to Soar? (Zacks)
Mar-19-24 04:48PM	Endocrine Disease-Focused Crinetics Pharmaceuticals Stock Soars On Tuesday - Here's Why (Benzinga) +19.11%
04:03PM	Crinetics Stock Jets 19% Higher, Reversing A Three-Week Decline On Its Phase 3 Win (Investor's Business Daily)

Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. The firm is also developing other oral nonpeptide somatostatin agonists for neuroendocrine tumors and hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease. The company was founded by R. Scott Struthers, Yun-Fei Zhu and Stephen F. Betz in 2008 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Betz Stephen F.	Chief Scientific Officer	Jun 12 '25	Option Exercise	3.30	88,170	291,078	197,196	Jun 16 04:48 PM
Betz Stephen F.	Chief Scientific Officer	Jun 12 '25	Sale	32.23	97,483	3,141,877	99,713	Jun 16 04:48 PM
STEPHEN BETZ	Officer	Jun 12 '25	Proposed Sale	32.33	97,483	3,151,625		Jun 12 04:19 PM
Struthers Richard Scott	President & CEO	Apr 02 '25	Option Exercise	1.91	81,270	155,226	410,417	Apr 04 04:30 PM
Pizzuti Dana	Chief Med and Dev Officer	Mar 19 '25	Sale	34.20	2,515	86,021	72,233	Mar 21 06:34 PM
Knight Jeff E.	Chief Operating Officer	Mar 19 '25	Sale	34.20	7,162	244,964	87,491	Mar 21 06:33 PM
Betz Stephen F.	Chief Scientific Officer	Mar 19 '25	Sale	34.20	5,770	197,353	108,588	Mar 21 06:32 PM
Struthers Richard Scott	President & CEO	Mar 19 '25	Sale	34.20	17,338	593,017	329,147	Mar 21 06:31 PM
Pizzuti Dana	Chief Med and Dev Officer	Feb 03 '25	Option Exercise	16.89	5,000	84,450	36,748	Feb 05 04:30 PM
Pizzuti Dana	Chief Med and Dev Officer	Feb 03 '25	Sale	39.07	5,000	195,350	31,748	Feb 05 04:30 PM
DANA J PIZZUTI	Officer	Feb 03 '25	Proposed Sale	39.07	5,000	195,372		Feb 03 04:11 PM
Pizzuti Dana	Chief Med and Dev Officer	Jan 03 '25	Option Exercise	16.89	15,000	253,350	44,248	Jan 07 04:30 PM
Pizzuti Dana	Chief Med and Dev Officer	Jan 07 '25	Option Exercise	19.64	2,500	49,100	31,748	Jan 07 04:30 PM
Pizzuti Dana	Chief Med and Dev Officer	Jan 03 '25	Sale	52.09	15,000	781,350	29,248	Jan 07 04:30 PM
DANA J PIZZUTI	Officer	Jan 03 '25	Proposed Sale	52.09	15,000	781,323		Jan 03 04:12 PM
Betz Stephen F.	Chief Scientific Officer	Dec 16 '24	Option Exercise	1.91	2,331	4,452	71,358	Dec 18 04:30 PM
Struthers Richard Scott	President & CEO	Dec 02 '24	Sale	57.57	10,000	575,700	100,000	Dec 04 04:30 PM
Struthers Richard Scott	Officer	Dec 02 '24	Proposed Sale	57.27	10,000	572,700		Dec 02 04:06 PM
Knight Jeff E.	Chief Operating Officer	Nov 22 '24	Sale	56.52	501	28,317	51,653	Nov 26 04:30 PM
Pizzuti Dana	Chief Med and Dev Officer	Oct 03 '24	Option Exercise	16.89	14,375	242,794	42,882	Oct 07 07:55 AM
Pizzuti Dana	Chief Med and Dev Officer	Oct 03 '24	Sale	54.63	14,375	785,306	28,507	Oct 07 07:55 AM
DANA J PIZZUTI	Officer	Oct 03 '24	Proposed Sale	54.63	14,375	785,322		Oct 03 04:08 PM
Wilson Marc	CFO	Sep 26 '24	Option Exercise	15.29	25,000	382,250	136,092	Sep 30 05:01 PM
Wilson Marc	CFO	Sep 26 '24	Sale	51.11	25,000	1,277,750	111,092	Sep 30 05:01 PM
MARC WILSON	Officer	Sep 26 '24	Proposed Sale	51.10	25,000	1,277,625		Sep 26 04:06 PM
Betz Stephen F.	Chief Scientific Officer	Sep 10 '24	Sale	51.50	1,035	53,302	68,576	Sep 12 04:30 PM
Betz Stephen F.	Officer	Sep 10 '24	Proposed Sale	51.50	1,035	53,301		Sep 10 12:11 PM
Betz Stephen F.	Chief Scientific Officer	Aug 26 '24	Sale	53.19	3,000	159,570	69,611	Aug 28 04:31 PM
Betz Stephen F.	Officer	Aug 26 '24	Proposed Sale	53.19	3,000	159,570		Aug 26 01:16 PM
Betz Stephen F.	Chief Scientific Officer	Aug 12 '24	Sale	47.68	3,000	143,040	72,611	Aug 14 04:30 PM
Betz Stephen F.	Officer	Aug 12 '24	Proposed Sale	47.68	3,000	143,050		Aug 12 11:35 AM
Betz Stephen F.	Chief Scientific Officer	Jul 25 '24	Sale	53.43	3,000	160,290	75,611	Jul 26 04:38 PM
Wilson Marc	CFO	Jul 25 '24	Option Exercise	9.28	19,056	176,840	130,148	Jul 26 04:24 PM
Wilson Marc	CFO	Jul 25 '24	Sale	53.88	19,056	1,026,737	111,092	Jul 26 04:24 PM
Knight Jeff E.	Chief Operating Officer	Jul 15 '24	Option Exercise	22.59	26,073	589,116	78,653	Jul 17 05:35 PM
Knight Jeff E.	Chief Operating Officer	Jul 15 '24	Sale	55.00	27,000	1,485,000	51,653	Jul 17 05:35 PM
Wilson Marc	CFO	Jul 15 '24	Option Exercise	20.02	25,000	500,500	136,092	Jul 17 05:14 PM
Wilson Marc	CFO	Jul 15 '24	Sale	55.00	25,000	1,375,000	111,092	Jul 17 05:14 PM
Betz Stephen F.	Chief Scientific Officer	Jul 10 '24	Sale	48.55	3,000	145,650	78,611	Jul 12 04:30 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CRNX

Crinetics Pharmaceuticals Inc

Upgrade your FINVIZ experience